L3VLUP
ProSign in

JNJ · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

JNJGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • JNJ
  • GILD
0204060202120222023202420252026
Holders and value by quarter
QuarterJNJGILD
Q3 202030 holders, $26.2bn25 holders, $14.2bn
Q4 202032 holders, $26.6bn27 holders, $13.4bn
Q1 202131 holders, $25.3bn24 holders, $14.5bn
Q2 202137 holders, $25.6bn18 holders, $14.9bn
Q3 202140 holders, $24.1bn20 holders, $16.4bn
Q4 202133 holders, $25.2bn20 holders, $16.8bn
Q1 202235 holders, $28.2bn28 holders, $13.2bn
Q2 202233 holders, $26.9bn26 holders, $13.6bn
Q3 202236 holders, $25.4bn24 holders, $13.3bn
Q4 202235 holders, $27.6bn32 holders, $21.1bn
Q1 202342 holders, $24.5bn27 holders, $21.8bn
Q2 202338 holders, $25.0bn24 holders, $20.7bn
Q3 202337 holders, $18.9bn24 holders, $20.0bn
Q4 202331 holders, $19.0bn22 holders, $21.5bn
Q1 202432 holders, $19.7bn30 holders, $20.3bn
Q2 202435 holders, $20.4bn28 holders, $18.5bn
Q3 202428 holders, $22.3bn29 holders, $24.2bn
Q4 202437 holders, $20.4bn28 holders, $25.9bn
Q1 202532 holders, $20.5bn33 holders, $32.0bn
Q2 202531 holders, $18.4bn27 holders, $30.9bn
Q3 202532 holders, $23.7bn23 holders, $29.4bn
Q4 202529 holders, $27.8bn25 holders, $34.3bn
Q1 202634 holders, $35.6bn25 holders, $38.5bn
Q2 202633 holders, $39.1bn26 holders, $34.2bn
JNJ

Johnson & Johnson

Holders
35
Reported value
$20.4bn
Buyers
24
Sellers
8

Breadth +16 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
GILD

Gilead Sciences Inc

Holders
28
Reported value
$18.5bn
Buyers
15
Sellers
14

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2024

Among the 40 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only JNJ (12)

Brevan Howard Capital Management LP, Caxton Associates LLP, Citadel Advisors LLC, GAMCO Investors Inc, Jane Street Group LLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Quantbot Technologies LP, Verition Fund Management LLC, Walleye Capital LLC

Only GILD (5)

Capital World Investors, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC, Tudor Investment Corp, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →